# A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

> **NCT05811416** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 200 (estimated)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis (RRMS)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05811416
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-14
- **Primary completion:** 2026-11-09
- **Final completion:** 2026-11-09
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05811416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05811416, "A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05811416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*